SCHEMBL10144292

SCHEMBL10144292

CCCCCCCCCCCCCCCc1c(C(C)=O)sc2c(Br)csc12

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 10/20 0.80
RARB P10826 4/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
RARA P10276 1/20 0.33
MAPT P10636 1/20 0.33
MTOR P42345 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 2/20 0.33
CA2 P00918 1/20 0.33
THRA P10827 1/20 0.33
THRB P10828 1/20 0.33
LMNA P02545 1/20 0.33
ESR1 P03372 1/20 0.33
SHBG P04278 1/20 0.33
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
ADRA2A P08913 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
HSPD1 P10809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10144290 1.00 GPR35 (0.80) GPR35RARBALDH1A1MEN1RARA
SCHEMBL13961890 1.00 GPR35 (0.80) GPR35RARBALDH1A1MEN1RARA
SCHEMBL10144291 1.00 GPR35 (0.80) GPR35RARBALDH1A1MEN1RARA
SCHEMBL13961888 1.00 GPR35 (0.80) GPR35RARBALDH1A1MEN1RARA
SCHEMBL13961913 0.93 GPR35 (0.70) GPR35RARBALDH1A1MEN1RARA
SCHEMBL2278156 0.89 GPR35 (1.00) GPR35RARBALDH1A1MEN1RARA
SCHEMBL437806 0.89 GPR35 (1.00) GPR35RARBALDH1A1MEN1RARA
SCHEMBL404495 0.89 GPR35 (1.00) GPR35RARBALDH1A1MEN1RARA
SCHEMBL407354 0.89 GPR35 (1.00) GPR35RARBALDH1A1MEN1RARA
SCHEMBL400817 0.89 GPR35 (1.00) GPR35RARBALDH1A1MEN1RARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120295965-A1 FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER CORNING INCORPORATED 2012-11-22 US disclosed
US-20120022116-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX CORNING INCORPORATED 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022116-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX GPR35, GPR65, GPR68 GPR35 1/4885RARB 717/4885ALDH1A1 1572/4885
US-20120295965-A1 FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER EGFR, ERBB2, KDR GPR35 1127/4885RARB 1054/4885ALDH1A1 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.